Romidepsin (FK228, Depsipeptide)

Catalog No.S3020 Synonyms: FR 901228, NSC 630176

Romidepsin (FK228, Depsipeptide) Chemical Structure

Molecular Weight(MW): 540.7

Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.

Size Price Stock Quantity  
USD 157 In stock
USD 477 In stock
USD 697 In stock
Bulk Discount
Bulk Inquiry

Free Overnight Delivery on orders over $ 500
Next day delivery by 10:00 a.m. Order now.

Cited by 30 Publications

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.
Features More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.
Targets
HDAC1 [1]
(Cell-free assay)		 HDAC2 [1]
(Cell-free assay)
36 nM 47 nM
In vitro

Unlike TSA, the active form redFK of Romidepsin strongly inhibits HDAC1 and HDAC2 with IC50 of 1.6 nM and 3.9 nM, respectively, but is relatively weak in inhibiting HDAC4 and HDAC6 with IC50 25 nM and 790 nM, respectively. Romidepsin is 17-23 times weaker than redFK in inhibiting these HDACs with IC50 of 36 nM, 47 nM, 510 nM, and 14 μM, respectively. Romidepsin treatment in HeLa cells induces histone acetylation and p21 expression with EC50 of 3.0 nM, more strongly than redFK with EC50 of 11 nM due to the instability of redFK. [1] In addition to G2/M arrest, Romidepsin treatment causes cyclin D1 downregulation and a p53-independent p21 induction, leading to inhibition of CDK and dephosphorylation of Rb resulting in growth arrest in the early G1 phase. [2] Romidepsin is 100 times more potent than TSA and 1,000,000 times more potent than butyrate in inhibiting the proliferation of the A549 cells. [3] Romidepsin inhibits the growth of U-937, K562, and CCRF-CEM cells with IC50 of 5.92 nM, 8.36 nM, and 6.95 nM, respectively. [5] Romidepsin promotes apoptosis in chronic lymphocytic leukemia (CLL) cells at a concentration corresponding to that at which H3 and H4 acetylation and HDAC inhibition occurs, selectively involving activation of caspase 8 and effector caspase 3, as well as down-regulation of c-FLIP protein. [6] In 11 of 13 (85%) renal cell carcinoma cell lines and in 16 of 37 (43%) other cancer cell lines, Romidepsin treatment up-regulates tumor death receptors, and potentiates natural killer (NK)-mediated tumor killing. [7] Romidepsin exhibits concentration-dependent cytotoxicity against a panel of mantle cell lymphoma (MCL) cell lines. [9]
Cell Data
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SU-DHL4 NIPyTW9E\WyuIG\pZYJqdGm2eTDBd5NigQ>? M2e2Z|IvPS1zNTDuUS=> M2jIc|czKGh? NVr3UmY2cW6mdXPld{BkgXSxdH;4bYNqfHliaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XMEoB?= M{PGdFI2PzlyOUC3
U2932  M1;0TWNmdGxiVnnhZoltcXS7IFHzd4F6 MWmyMlUuOTVibl2= NYLF[WZ4PzJiaB?= MUXpcoR2[2W|IHP5eI91d3irY3n0fUBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7lduKh NYXMVYVHOjV5OUC5NFc>
OCI-LY7 MU\D[YxtKF[rYXLpcIl1gSCDc4PhfS=> M{nOd|IvPS1zNTDuUS=> NXzOcGpSPzJiaB?= M17afIlv\HWlZYOgZ5l1d3SxeHnjbZR6KGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVzyqB? M2P1flI2PzlyOUC3
Farage M4C3bGNmdGxiVnnhZoltcXS7IFHzd4F6 NH3SUFgzNjVvMUWgcm0> MYm3NkBp MliybY5lfWOnczDjfZRwfG:6aXPpeJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>? MmGyNlU4QTB7MEe=
LY7/EBV MU\D[YxtKF[rYXLpcIl1gSCDc4PhfS=> NHnCToQzNjVvMUWgcm0> MoHiO|IhcA>? NVHORmQ{cW6mdXPld{BkgXSxdH;4bYNqfHliaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XMEoB?= NGW4Rm4zPTd7MEmwOy=>
U2932/EBV NFW2e3ZE\WyuIG\pZYJqdGm2eTDBd5NigQ>? M1PCc|IvPS1zNTDuUS=> NXzaR3N5PzJiaB?= MkC0bY5lfWOnczDjfZRwfG:6aXPpeJkhcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZLDqA>? MknINlU4QTB7MEe=
HCT116 NVrwZnpCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUez[oY1PS13MECwJI5O M1nMZlI1KGh? NXnvdmJkTE2VTx?= M3PY[4lv\HWlZYOgZ4VtdCCmZXH0bEBqdiCjIHPvcoNmdnS{YYTpc44u\GWyZX7k[Y51KG2jbn7ldi=> MoTyNlU1QTJ3MUW=
ACH-2 MXXGeY5kfGmxbjDBd5NigQ>? M{TEdlEuQSCwTR?= NV3WW2Z1OjRiaB?= NXe3[lJRcW6mdXPld{BJUVZvMTDFcpYh\XiycnXzd4lwdg>? MWiyOVE1QTR4Nx?=
MCF-10A NFm5VpNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV3jeYhuUUN3ME2wMlE4yrFyLkCxJI5O M3P4PVI1QTV2OEW2
MCF-7 M4G4eWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NF3YPG5KSzVyPUGuNVDDuTBwMkCgcm0> M3j0bFI1QTV2OEW2
SK-BR-3 MmD5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{jKV2lEPTB;MT6wNOKyOC5|NTDuUS=> NVvQSVJpOjR7NUS4OVY>
MDA-MB-231 M3vPT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXjrelZPUUN3ME2wMlY5yrFyLkG0JI5O MlXHNlQ6PTR6NU[=
PC3 M1zIOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rjXGlEPTB;MT62OeKyOC5|NTDuUS=> MmLHNlQ6PTR6NU[=
HCT116 NGXFS2VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV\JR|UxRTFwMEFCtVAvODBibl2= M2LmPVI1QTV2OEW2
HCT116-p21-/- NV3sSGk{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mo[5TWM2OD1zLkK2xtExNjN5IH7N MUOyOFk2PDh3Nh?=
S1 M2nJNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M13rfGlEPTB;Nz62O:KyOC5{OTDuUS=> M{\OdlI1QTV2OEW2
SW620 Mnu5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NU\RfWYxUUN3ME2wMlk{yrFyLkK5JI5O NIPUS|czPDl3NEi1Oi=>
LOX-IMVI NFvYcpVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWjIeJlUUUN3ME2wMlg4yrFyLkCzJI5O NIHsRXczPDl3NEi1Oi=>
UACC-62 MkfHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrnUWdnUUN3ME2wMlU3yrFyLkG2JI5O M1XpXlI1QTV2OEW2
MDA-MB-435 NEi2U4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3Hjc2lEPTB;MD65NOKyOC5yNjDuUS=> NV7LZ3JxOjR7NUS4OVY>
SF-295 NVTLc3Z3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUPJR|UxRTBwOElCtVAvOTVibl2= NXzTZo9ZOjR7NUS4OVY>
A549 NHPPZYhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIf6XVRKSzVyPUGuNlbDuTBwMkSgcm0> NU\TTowyOjR7NUS4OVY>
H460 NIjpTIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlPVTWM2OD1{LkW4xtExNjhyIH7N MkLQNlQ6PTR6NU[=
EKVX MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGi3TodKSzVyPUGuN|PDuTBwM{Sgcm0> NG\JZ28zPDl3NEi1Oi=>
H146 M{DP[Wdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkHRTWM2OD1yLkKyxtExNjB5IH7N MkHNNlQ6PTR6NU[=
H526 M3nGZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4TROGlEPTB;MD6xOeKyOC5yMzDuUS=> NH7DNXMzPDl3NEi1Oi=>
HuT-78 MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml7lTWM2OD1zLkezxtExNjR2IH7N MkLoNlQ6PTR6NU[=
HA MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFzzS4QxNjZ{NT2xNI5O NV7DSopVPDhiaB?= NX\xS3hlcW6mdXPld{BiKHOrZ37p[olk[W62bImgd5Rzd26pZYKgbY5pcWKrdHnvckBw\iClZXzsJJBzd2yrZnXyZZRqd25iY3:teJJm[XSnZDD3bZRpKGKxcoTlfo9ucWJ? MWeyOFc4OTVzMB?=
MS-275 NG\xOGxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnJb3cxNjZ{NT2xNI5O M{Pyc|Q5KGh? MXnpcoR2[2W|IHGgd4lodmmoaXPhcpRtgSC|dILvcodmeiCrbnjpZol1cW:wIH;mJINmdGxicILvcIln\XKjdHnvckBkdy22cnXheIVlKHerdHigZo9zfGW8b33pZi=> NWC1bJN7OjR5N{G1NVA>
CD4 T NV2wS2ZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4PDVVQ5KGh? MYHFR|UxRTRwNdMxNU4xKG6P NV3pe5RxOjR5MkK0OVQ>
CD4 T NXSxU4Q5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX7wNZJVPDhiaB?= M1:ydWNEPTB;MUC3xtEyOjZibl2= MVmyOFczOjR3NB?=
CD4+ T M3LDV2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUTFR|UxRTNibl2= MojkNlQ1QTVzMEW=
A549 NGL1SoxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWCxNQKBmzFyMNMgcm0> NYWwUVAzOjRxM{[vOFghcA>? NEPRdIZqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKGOxbnPlcpRz[XSrb36tJIFv\CC2aX3lMYRmeGWwZHXueEBu[W6wZYK= NF;nelAzPDR6NUe5PS=>
JJN3 NWi3dHE2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2\rclI1NzR6IHi= MXvFR|UxRDIkgJnuUVshPDkkgJno NYfYOldXOjRyM{CxOVA>
OPM-2 M3TrTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEHlUYszPC92ODDo NFL4ZpRGSzVyc{2x5qCKdk19IES45qCKcA>? NXfGcog4OjRyM{CxOVA>
RPMI-8226 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUm5UGF[OjRxNEigbC=> MnOwSWM2OHN;MT645qCKdk19IES45qCKcA>? NXy0XVdLOjRyM{CxOVA>
U266 MWTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYXYeYFWOjRxNEigbC=> NUO5RZh1TUN3MIO9NVDjiImwTUugOFjjiImq MV[yOFA{ODF3MB?=
CA46 NEfo[XlCeG:ydH;zbZMhSXO|YYm= M{fWfFYhcA>? MnSwbY5lfWOnczDicJVvfCCjcH;weI9{cXN? M3j0TFI{QTZ4MU[0
DG75 M{\iTWFxd3C2b4Ppd{BCe3OjeR?= NIjFfpY3KGh? MUfpcoR2[2W|IH7vJIFxd3C2b4Ppdy=> NV7v[pJROjN7Nk[xOlQ>
Ramos NVjlUWVFSXCxcITvd4l{KEG|c3H5 NHnr[YI3KGh? NGPOXpVqdmS3Y3XzJIV5fGWwc3n2[UBieG:ydH;zbZM> M3Lt[|I{QTZ4MU[0
ST486 MVnBdI9xfG:|aYOgRZN{[Xl? M3m0W|YhcA>? NGHLbGRqdmS3Y3XzJIV5fGWwc3n2[UBieG:ydH;zbZM> MWCyN|k3PjF4NB?=
HuT78 M2m5WGFxd3C2b4Ppd{BCe3OjeR?= M{Lw[FEwOTBxMUCwJI5O M4fHOlQ5KGh? NIfKemhqdmS3Y3XzJIFxd3C2b4Ppd{BifCBzIH7N Mn[xNlM2OzJ5M{K=
DpVp35 MnzzRZBweHSxc3nzJGF{e2G7 MoLuNU8yOC9zMECgcm0> NV7TV4VZPDhiaB?= NHH0SXhqdmS3Y3XzJIJtfW62IHHwc5B1d3Orcx?= NUL0UXNyOjN3M{K3N|I>
DpVp50 NYTve2ZHSXCxcITvd4l{KEG|c3H5 MXWxM|ExNzFyMDDuUS=> MX:0PEBp MkDubY5lfWOnczDicJVvfCCjcH;weI9{cXN? NYPwToxbOjN3M{K3N|I>
DpP75  M3fGfWFxd3C2b4Ppd{BCe3OjeR?= MVuxM|ExNzFyMDDuUS=> MU[0PEBp NYPTV2tqcW6mdXPld{BjdHWwdDDhdI9xfG:|aYO= NILtO2MzOzV|MkezNi=>
SKOV-3 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTXN2tnOeLCk{Kwcm0> NILTU2U4OiCq NXHufpFtTE2VTx?= MkHodoVlfWOnczDj[YxtKH[rYXLpcIl1gSCjbH;u[UBidmRiY3;tZolv\WRid3n0bEBkcXOybHH0bY4> M1nhXlI{ODFyM{S4
Brca1 WT NWLkb2R5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvteIIy6oDVMkDuUS=> NFLwTW84OiCq Moi2SG1UVw>? NWDzR2JGemWmdXPld{Bk\WyuII\pZYJqdGm2eTDhcI9v\SCjbnSgZ49u[mmwZXSge4l1cCClaYPwcIF1cW5? NV7WPXcyOjNyMUCzOFg>
Brca1 Null NIHEPJhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXSx5qCUOjCwTR?= M2PkSlczKGh? MV;EUXNQ NXfYTYdyemWmdXPld{Bk\WyuII\pZYJqdGm2eTDhcI9v\SCjbnSgZ49u[mmwZXSge4l1cCClaYPwcIF1cW5? MYSyN|AyODN2OB?=
OVCAR-8  NUXOTVBXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVix5qCUOjCwTR?= M2XsVFczKGh? MWjEUXNQ MoDKdoVlfWOnczDj[YxtKH[rYXLpcIl1gSCjbH;u[UBidmRiY3;tZolv\WRid3n0bEBkcXOybHH0bY4> Ml7PNlMxOTB|NEi=
NCI/ADR-RES NEHPWIdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYmx5qCUOjCwTR?= NFPGVXc4OiCq NXuxdlJITE2VTx?= M3u3S5Jm\HWlZYOgZ4VtdCC4aXHibYxqfHliYXzvcoUh[W6mIHPvcYJqdmWmIIfpeIgh[2m|cHzheIlv MkLENlMxOTB|NEi=
HCT116 NVu0SHNyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWO1JI5ONTVyIN88US=> NHzDZYEzPCCq M1u2[WROW09? M{LGW4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz NF\tN|MzOjl{NEm1PC=>
RKO NIO1[ZhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{jqSlUhdk1vNUCg{txO MoLaNlQhcA>? M{TncGROW09? MoXVbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDjc45k\W62cnH0bY9vNWSncHXu[IVvfCCvYX7u[ZI> NIrZTYkzOjl{NEm1PC=>
CO115 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVm1JI5ONTVyIN88US=> Ml7xNlQhcA>? NXvjRpdZTE2VTx?= NYPCdGlJcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBkd26lZX70doF1cW:wLXTldIVv\GWwdDDtZY5v\XJ? NUHKfI93OjJ7MkS5OVg>
HFS NIniPZFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWC1JI5O MnzTNlQwPDhxN{KgbC=> NETLZWxqdmirYnn0d{Bk\WyuIHfyc5d1cCC2aX3lMYRmeGWwZHXueIx6 Mny2NlIyODZ{OEK=
LNCaP MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVTqO4NQPSCwTR?= MmTRNlQwPDhxN{KgbC=> NFrJdXRqdmirYnn0d{Bk\WyuIHfyc5d1cCC2aX3lMYRmeGWwZHXueIx6 MkLHNlIyODZ{OEK=
A549 NEmyUGRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3O1VVUhdk1? NVLLfGVyOjRxNEivO|IhcA>? NEHGUlNqdmirYnn0d{Bk\WyuIHfyc5d1cCC2aX3lMYRmeGWwZHXueIx6 NUPsZnV6OjJzME[yPFI>
697  NHHnWIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYezbVJ5UUN3MPMAjV3jiIl{LkZCpI5O NH\FPZkzOTV|OEKxOi=>
697-R MmrYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HqdGlEPTEkgJm95qCKQC54wrDuUeKh NWnCdGNOOjF3M{iyNVY>
HUT78 MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MX;JR|UxRTFibl2= NGrRWHAzOTF7OEW0OS=>
THJ-16T NYfoRYdXT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHLmUokyKG6P MnfVNlQhcA>? M3LSRYlvcGmkaYTzJINmdGxiZ4Lve5Rp NHXT[GUzODhzMEW2PC=>
HCT116 NXvVNWtQTnWwY4Tpc44hSXO|YYm= NVTLRmJ1OjBibl2= NV\1e5FZQCCq M3TSOo1w\HWuYYTld{B1emGwc3PybZB1KGyndnXsd{Bnd3JiaIXu[JJm\HNib3[g[4Vv\XNiaX6g[Yl1cGW{IHTpdoVkfGmxbh?= NXPYTZpkOjB5M{m0OVQ>
B104  MnLGSpVv[3Srb36gRZN{[Xl? NXjndWpCOiCwTR?= NUfuS5V2OjRxNEivO|IhcA>? M1HD[olv[3KnYYPld{B1cGVic4Xy[oFk\SCneIDy[ZN{cW:wIH;mJGNFOjEEoB?= MkCzNlA3QDZ3MEW=
HL-60  M1XU[GN6fG:2b4jpZ4l1gSCDc4PhfS=> NX\CRXFNOS13MECgcm0> NWTFN|lvOjRiaB?= NI\Fe3JqdmS3Y3XzJIN6fG:2b4jpZ4l1gSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5mesLi Ml;uNlA3OjRzNkO=
HP100 NFnNenVEgXSxdH;4bYNqfHliQYPzZZk> NHrPTIEyNTVyMDDuUS=> MWiyOEBp NFPxVmNqdmS3Y3XzJIN6fG:2b4jpZ4l1gSCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5mesLi MlzrNlA3OjRzNkO=
HL-60  Ml\HSpVv[3Srb36gRZN{[Xl? MV:xNEBvVQ>? MWm0M|YwOTZiaB?= M{\sPIlv\HWlZYOgeIhmKGenbnXyZZRqd25ib3[gbJllem:pZX6gdIVzd3irZHWg[pJwdSB2aB?= Mkj3NlA3OjRzNkO=
HP100 MXjGeY5kfGmxbjDBd5NigQ>? MlPYNVAhdk1? MWW0M|YwOTZiaB?= Ml6zbY5lfWOnczD0bIUh\2WwZYLheIlwdiCxZjDofYRzd2enbjDw[ZJwgGmmZTDmdo9uKDSq MV[yNFYzPDF4Mx?=
HL-60  NWfUU|NnTnWwY4Tpc44hSXO|YYm= M33CNlExNTVyMDDuUS=> NHfkdFI1KGh? M{PCNoRm[3KnYYPld{B1cGViaHnzeI9v\SCmZXHj[ZR6dGG|ZTCoTGRCSyliYXP0bZZqfHoEoB?= NFz1dGIzODZ{NEG2Ny=>
HP100 M3jiZmZ2dmO2aX;uJGF{e2G7 NYfWXJg6OTBvNUCwJI5O NGPUUow1KGh? M4TaWoRm[3KnYYPld{B1cGViaHnzeI9v\SCmZXHj[ZR6dGG|ZTCoTGRCSyliYXP0bZZqfHoEoB?= NWf2Ood1OjB4MkSxOlM>
11z MYnLbY5ie2ViQYPzZZk> MoH1N{0yODBibl2= NGK5[oNz\WS3Y3XzJGhFSUNiZX76fY1ifGmlIHHjeIl3cXS7IDjJR|UxyqB;IE[uOUDDuSByLk[gco1wdC:OKR?= NFPTbVUzODZyNUG0OC=>
SKOV-3 MoTaS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NH\n[lE1NzhxMU[gcm0> NET4[5g1QCCq M{TC[4lvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGgZ49v[2WwdILheIlwdi2mZYDlcoRmdnRibXHucoVz NILMVIMzODRyNEW2OC=>
OVCAR-3 MoDHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M132NVQwQC9zNjDuUS=> MkK5OFghcA>? NF\OOpBqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJINwdmOnboTyZZRqd25vZHXw[Y5l\W62IH3hco5meg>? NU[3dnM5OjB2MES1OlQ>
HBL-2 MV3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYLvUZFmOi1zMDDuUS=> NEGxcXAzPCCq MWDJR|UxRTRwMzDuUS=> NIPl[YMzODB4OEC4NC=>
Jeko-1 M2DkXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPLSoMzNTVyIH7N NYjuS2lUOjRiaB?= MoDlTWM2OD1zMTDuUS=> M2P6TFIxODZ6MEiw
Granta-519 M4LIUGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnXhOU01OCCwTR?= M3vWSVI1KGh? NXjxW2lMUUN3ME21PE42KG6P NVLwOng6OjByNkiwPFA>
L1236 NIn5ZVFEgXSxdH;4bYNqfHliQYPzZZk> NFryTYsyKG6PLUGwNEDPxE1? M1LkR|Q5KGh? Mn;rSWM2OD1yLkC3JO69VQ>? MYSxPVI{OzR5MB?=
L428 NVOzV|dWS3m2b4TvfIlkcXS7IFHzd4F6 MUWxJI5ONTFyMDFOwG0> MofrOFghcA>? NUf3e5FNTUN3ME2wMlQ{KM7:TR?= MXuxPVI{OzR5MB?=
KM-H2 MV;DfZRwfG:6aXPpeJkhSXO|YYm= MmfwNUBvVS1zMECg{txO NUHoZ4xNPDhiaB?= MoX2SWM2OD1yLkW4JO69VQ>? NY\SPYMyOTl{M{O0O|A>
L540Cy MoTDR5l1d3SxeHnjbZR6KEG|c3H5 NFnmdZIyKG6PLUGwNEDPxE1? MVi0PEBp NE\SbmJGSzVyPUCuNVYh|ryP M2PON|E6OjN|NEew
G401 NEPhVWxHfW6ldHnvckBCe3OjeR?= NH\hZXYyOCCwTR?= MYmyOE81QC95MjDo NVT0OVNVTE2VTx?= NX;3SY9PcW6lcnXhd4V{KEOGS16xR{BmgHC{ZYPzbY9v M4O2NVE6OjJzNUi2
STM91-01 NV;udVRbTnWwY4Tpc44hSXO|YYm= NEP4ZZYyOCCwTR?= MkfzNlQwPDhxN{KgbC=> NF3KRpdFVVOR NFvkSHJqdmO{ZXHz[ZMhS0SNTkHDJIV5eHKnc4Ppc44> MU[xPVIzOTV6Nh?=
SJSC  NHPwempHfW6ldHnvckBCe3OjeR?= NIjWOYgyOCCwTR?= MkW3NlQwPDhxN{KgbC=> NFvnb4NFVVOR NYPieIpLcW6lcnXhd4V{KEOGS16xR{BmgHC{ZYPzbY9v MkXFNVkzOjF3OE[=
BT16  M2DMc2Z2dmO2aX;uJGF{e2G7 MUmxNEBvVQ>? NX3QV|F5OjRxNEivO|IhcA>? MmTWSG1UVw>? MoGwbY5kemWjc3XzJGNFU05zQzDlfJBz\XO|aX;u NYC1OHM5OTl{MkG1PFY>
NCI-H1299 NVjYOJB5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVOxVIcyUUN3ME20MlbDuTBwMjDu[{9udA>? MoLnNVkyPzl6OUC=
NCI-2882 MmjoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{DrNmlEPTB;MT62xtExNjB2IH7nM41t NHTFenkyQTF5OUi5NC=>
HCC95 Mkn4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXPJR|UxRTJwNdMxNE4xPSCwZz;tcC=> M4LiSVE6OTd7OEmw
NCI-H23 MYXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlfiTWM2OD1{LkpCtVAvOiCwZz;tcC=> MVSxPVE4QTh7MB?=
NCI-H157 NFLsR|VIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH3nR5pKSzVyPUGuOuKyOC5yMjDu[{9udA>? MV2xPVE4QTh7MB?=
NCI-H460 Mn7zS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MX;JR|UxRTJwMdMxNE4xPyCwZz;tcC=> Mn;UNVkyPzl6OUC=
NCI-H1975 NWe2[pZpT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYXJR|UxRTFwM9MxNE4xPCCwZz;tcC=> NX7nPGwxOTlzN{m4PVA>
NCI-H820 M1[4T2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFm0VWVKSzVyPUKuOOKyOC5zIH7nM41t Mk[5NVkyPzl6OUC=
NCI-H1650 MYLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{jHfGlEPTB;ND65xtExNjNibnevcYw> M{K0XFE6OTd7OEmw
DTC1 MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIHoOJhKSzVyPUCuOVEhdk1? MorXNVg2PjZ{NE[=
KAO NYnnRoZHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGnLSWdKSzVyPUCuPVEhdk1? NGfHPZIyQDV4NkK0Oi=>
SU-CCS-1 MoHBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmTnTWM2OD1yLki5JI5O MUexPFU3PjJ2Nh?=
SYO-1 NHf3UHdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NV71W4RyUUN3ME2wMlY4KG6P NWe1OXBSOTh3Nk[yOFY>
FUJI Ml\vS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGruTZhKSzVyPUGuN|Ehdk1? M1T3cVE5PTZ4MkS2
SKNMC NVrwPVY{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3TwVWlEPTB;MT6xO{BvVQ>? NEDpZVUyQDV4NkK0Oi=>
402-91 NEPhdppIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV3JR|UxRTFwMk[gcm0> NUi4eYpROTh3Nk[yOFY>
1765-92 M1HFNWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlrhTWM2OD1zLke3JI5O M2TiOFE5PTZ4MkS2
JN-DSRCT-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUHJR|UxRTFwMkWgcm0> NWnmfnpCOTh3Nk[yOFY>
NMS-2PC NWfJUYY5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{LXTGlEPTB;MD64NUBvVQ>? M4LpZlE5PTZ4MkS2
HL60 M2qwSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXLS[GZmUUN3ME2xMlg3KG6P NFXMRXcyQDV4NkK0Oi=>
A549 NUf2XGE1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUTtSIV6UUN3ME2zMlI1KG6P NXTmS3l7OTh3Nk[yOFY>
SW480 NGjJN5dIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWXCNGhYUUN3ME2yMlY6KG6P M{D4T|E5PTZ4MkS2
MCF7 NV22RVlST3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWLJR|UxRTNwNUWgcm0> MWqxPFU3PjJ2Nh?=
PC-3 NUPOZ2hCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{PVbGlEPTB;Mj61NUBvVQ>? NWjhb|hPOTh3Nk[yOFY>
MMRU MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NIfXWZZKSzVyPUKuOVchdk1? M4jZS|E5PTZ4MkS2
Hs68 NX:4R5g1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVrJR|UxRT5zMDDuUS=> NUi3[ZkyOTh3Nk[yOFY>
hMSC-001F M{PLO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkfITWM2OD1-MUCgcm0> MYGxPFU3PjJ2Nh?=

... Click to View More Cell Line Experimental Data
Assay
Methods Test Index PMID
Western blot
p21 / Cyclin D1; 

PubMed: 19682393     


NIH 3T3 cells stably expressing the indicated proteins were treated with DMSO (Vehicle) or the indicated concentration of romidepsin for 24 h. Cell lysates were analyzed by western blotting with antibodies to cyclin D1, p21 and β-actin (loading control). Data shown are representative of at least two independent experiments.

AcH3(K9) / Ac-α-Tubulin(K40) / Ac-NFκB2(K310) p65 / 3MeH3(K27); 

PubMed: 26473529     


Effects of romidepsin (Rom) on the levels of acetylated proteins and related enzymes. Cells were exposed to romidepsin for 48 h and total cell extracts were analyzed by western blot.

HDAC3 / HDAC4 / HDAC6 / HDAC2; 

PubMed: 26473529     


Effects of romidepsin (Rom) on the levels of acetylated proteins and related enzymes. Cells were exposed to romidepsin for 48 h and total cell extracts were analyzed by western blot.

γH2AX / PARP1 / Cleaved caspase3 / BAK / p21(waf1/cip1) / XIAP; 

PubMed: 26473529     


Western blot analysis of proteins involved in DNA-damage response and apoptosis. Established cell lines were exposed to different concentrations of romidepsin (Rom) for 48 h and total cell extracts were analyzed.

Cyclin E1 / BRCA1 / E2F1 / Cleaved PARP / H3Ac; 

PubMed: 27444036     


Western blot analysis of the effects of panobinostat (25 nM), vorinostat (5 µM) and romidepsin (10 nM) on expression of cyclin E1, E2F1, BRCA1, cleaved PARP and acetylated histone H3 in OVCAR-3 cells. Actin and histone H3 were loading controls. 

pAKT(S473) / pAKT(T308) / AKT; 

PubMed: 25492515     


Western blot analysis of phosphorylated AKT in PC3 cells. Cells were treated for 3 h with various concentrations of FK228. 

19682393 26473529 27444036 25492515
Growth inhibition assay
Cell viability; 

PubMed: 27444036     


Concentration-dependent effects of panobinostat and vorinostat in SRB viability assays in OVCAR-3 cells (72 h). Values are mean+SE of 3 independent experiments. 

27444036
Immunofluorescence
SS18/TLE1; 

PubMed: 27120803     


A significant decrease in detectable PLA signal following HDAC inhibition in SYO-1 cells.

Cleaved caspase-3; 

PubMed: 22531354     


TDP-B activates cleaved caspase-3 by immunofluorescence. Representative immunofluorescence staining for cleaved caspase 3 (green) in SKOV-3 ovarian cancer cells treated with 10 nM FK228, TDP-A or TDP-B after 24 h of exposure. The nuclei are stained with DAPI (blue).

27120803 22531354
In vivo Romidepsin treatment potently inhibits the neovascularization of chick embryo and that of adult mice in the Matrigel plug assay. [4]Administration of Romidepsin at 0.1-1 mg/kg twice a week significantly prolongs the survival of mice bearing U-937 lymphoma, with median survival times of 30.5 (0.56 mg/kg) and 33 days (0.32 mg/kg), respectively (vs. 20 days in control mice). [5]

Protocol

Kinase Assay:

[1]
+ Expand

HDAC-inhibitory activity:

For the enzyme assay, 10 μL of [3H]acetyl-labeled histones (25,000 cpm/10 μg) are added to 90 μL of the HDAC enzyme fraction extracted from 293T cells overexpressing HDAC1 or HDAC2 in the presence of increasing concentrations of Romidepsin, and the mixture is incubated at 37 °C for 15 minutes. The enzyme reaction is linear for at least 1 hour. The reaction is stopped by the addition of 10 μL of concentrated HCl. The released [3H]acetic acid is extracted with 1 mL of ethylacetate, and 0.9 mL of the solvent layer is taken into 5 mL of aqueous counting scintillant II solution for determination of radioactivity. The IC50 values are determined from at least three independent dose-response curves.
Cell Research:

[3]
+ Expand
  • Cell lines: HL60, Jurkat, A549, and MCF-7
  • Concentrations: Dissolved in DMSO, final concentrations ~10 μM
  • Incubation Time: 72 hours
  • Method:

    Cells are exposed to various concentrations of Romidepsin for 72 hours in 96-well plates. 20 μL of 5 mg/mL MTT solution in PBS is added to each well for 4 hours. After removal of the medium, 170 μL of DMSO is added to each well to dissolve the formazan crystals. The absorbance at 540 nm is determined. In addition, cells are incubated with trypan blue, and the numbers of blue (dead) cells and transparent (live) cells are counted in a hemocytometer. For cell cycle analysis, cells are incubated for 30 minutes in propidium iodide staining solution containing 0.05 mg/mL propidium iodide, 1 mM EDTA, 0.1% Triton X-100, and 1 mg/mL RNase A in PBS. The suspension is then passed through a nylon mesh filter and analyzed on a Becton Dickinson FACScan.


    (Only for Reference)
Animal Research:

[5]
+ Expand
  • Animal Models: Male scid mice inoculated i.p. with U-937 cells
  • Formulation: Dissolved in DMSO, and diluted in saline
  • Dosages: ~1 mg/kg once or twice a week
  • Administration: Treated i.p.
    (Only for Reference)

Solubility (25°C)

In vitro DMSO 10 mg/mL (18.49 mM)
Water Insoluble
Ethanol Insoluble
In vivo Add solvents to the product individually and in order(Data is from Selleck tests instead of citations):
2% DMSO+30% PEG 300+5%Tween 80+ddH2O
For best results, use promptly after mixing. 		5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information

Molecular Weight 540.7
Formula

C24H36N4O6S2
CAS No. 128517-07-7
Storage powder
in solvent
Synonyms FR 901228, NSC 630176

Bio Calculators

Molarity Calculator

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

  • Mass
    Concentration
    Volume
    Molecular Weight

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration (start) x Volume (start) = Concentration (final) x Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

  • C1
    V1
    C2
    V2

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

  • Serial Dilutions

  • Computed Result

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
Molecular Weight Calculator

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Total Molecular Weight: g/mol

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Mass Concentration Volume Molecular Weight

Clinical Trial Information

NCT Number Recruitment Conditions Sponsor/Collaborators Start Date Phases
NCT03770000 Recruiting T Cell Lymphoma Rhizen Pharmaceuticals SA March 2019 Phase 1|Phase 2
NCT03770000 Recruiting T Cell Lymphoma Rhizen Pharmaceuticals SA March 2019 Phase 1|Phase 2
NCT03703375 Recruiting Lymphoma T-Cell Celgene November 6 2018 Phase 3
NCT03593018 Recruiting Relapsed Angioimmunoblastic T-Cell Lymphoma|Refractory Angioimmunoblastic T-cell Lymphoma The Lymphoma Academic Research Organisation|Celgene November 9 2018 Phase 3
NCT03703375 Recruiting Lymphoma T-Cell Celgene November 6 2018 Phase 3
NCT03593018 Recruiting Relapsed Angioimmunoblastic T-Cell Lymphoma|Refractory Angioimmunoblastic T-cell Lymphoma The Lymphoma Academic Research Organisation|Celgene November 9 2018 Phase 3

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

  • * Indicates a Required Field
selleck catalog

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Related HDAC Products4

  • LMK-235 New

    LMK-235 is a selective inhibitor of HDAC4 and HDAC5 with IC50 of 11.9 nM and 4.2 nM, respectively.

  • CAY10603 New

    CAY10603 is a potent and selective HDAC6 inhibitor with IC50 of 2 pM, >200-fold selectivity over other HDACs.

  • Domatinostat (4SC-202) New

    4SC-202 is a selective class I HDAC inhibitor with IC50 of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. Also displays inhibitory activity against Lysine specific demethylase 1 (LSD1). Phase 1.

  • Panobinostat (LBH589)

    Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Phase 3.

  • Vorinostat (SAHA, MK0683)

    Vorinostat (suberoylanilide hydroxamic acid, SAHA) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay.

  • Entinostat (MS-275)

    Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.

  • Trichostatin A (TSA)

    Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.

  • RGFP966

    RGFP966 is an HDAC3 inhibitor with IC50 of 0.08 μM in cell-free assay, exhibits > 200-fold selectivity over other HDAC.

  • Tubastatin A

    Tubastatin A is a potent and selective HDAC6 inhibitor with IC50 of 15 nM in a cell-free assay. It is selective against all the other isozymes (1000-fold) except HDAC8 (57-fold).

  • Mocetinostat (MGCD0103)

    Mocetinostat (MGCD0103) is a potent HDAC inhibitor with most potency for HDAC1 with IC50 of 0.15 μM in a cell-free assay, 2- to 10- fold selectivity against HDAC2, 3, and 11, and no activity to HDAC4, 5, 6, 7, and 8. Phase 2.

Tags: buy Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide) supplier | purchase Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide) cost | Romidepsin (FK228, Depsipeptide) manufacturer | order Romidepsin (FK228, Depsipeptide) | Romidepsin (FK228, Depsipeptide) distributor
×
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID